Table S2. Summary of the estimates and GRADE evidence in the analyses of clinical outcomes.
| Quality assessment | No of patients | Effect | Quality (importance) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Immunotherapy | Conventional therapy | Relative (95% CI) | Absolute | |
| Overall survival | |||||||||||
| 14 | Randomized trials | No serious risk of bias | No serious inconsistency | No serious indirectness | No serious imprecision | None detected | Not applicable | HR 0.65 (0.57 to 0.74) | Not applicable | ⊕⊕⊕⊕High (critical) | |
| Progression-free survival | |||||||||||
| 15 | Randomized trials | No serious risk of bias | No serious inconsistency | No serious indirectness | No serious imprecision | None detected | Not applicable | HR 0.81 (0.75 to 0.86) | Not applicable | ⊕⊕⊕⊕High (critical) | |
| 1-year overall survival | |||||||||||
| 14 | Randomized trials, samples: 1,858, events: 1,682 | No serious risk of bias | No serious inconsistency | No serious indirectness | No serious imprecision | None detected | 883/956 (92.4%) | 799/902 (88.6%) | RR 1.04 (1.01 to 1.07) | 27 more per 1,000 (from 0 more to 53 more) | ⊕⊕⊕⊕High (critical) |
| Moderate 90.4% | 27 more per 1,000 (from 0 more to 54 more) | ||||||||||
| 3-year overall survival | |||||||||||
| 12 | Randomized trials, samples: 1,624, events: 1,272 | No serious risk of bias | Seriousa | No serious indirectness | No serious imprecision | None detected | 697/841 (82.9%) | 575/783 (73.4%) | RR 1.11 (1.03 to 1.20) | 81 more per 1,000 (from 22 more to 147 more) | ⊕⊕⊕O Moderate (critical) |
| Moderate 78% | 86 more per 1,000 (from 23 more to 156 more) | ||||||||||
| 5-year overall survival | |||||||||||
| 8 | Randomized trials, samples: 1,126, events: 693 | No serious risk of bias | No serious inconsistency | No serious indirectness | No serious imprecision | None detected | 387/595 (65%) | 306/531 (57.6%) | RR 1.17 (1.06 to 1.28) | 81 more per 1,000 (from 12 more to 150 more) | ⊕⊕⊕⊕High (critical) |
| Moderate 52% | 73 more per 1,000 (from 10 more to 135 more) | ||||||||||
GRADE Working Group grades of evidence: ⊕⊕⊕⊕ High quality: further research is very unlikely to change our confidence in the estimate of the effect; ⊕⊕⊕O Moderate quality: further research is likely to have an important impact on our confidence in the estimate of the effect and may change the estimate; ⊕⊕OO Low quality: further research is very likely to have an important impact on our confidence in the estimate of the effect and is likely to change the estimate; ⊕OOO Very low quality: we are very uncertain about the estimate. a, downgraded (−1) for inconsistency: heterogeneity greater than 50% was observed in this subgroup. RR, risk ratio; HR, hazard ratio; and CI, confidence interval.